Savolitinib vs Tepotinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline

Savolitinib · Orpathys

Marketed by AstraZeneca and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT05015608 · Phase 3 · completed

The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT04322890 (registry estimate)

Reported efficacy

Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized): SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. (met)

Result source: NCT05261399

Tepotinib · Tepmetko

Marketed by Merck KGaA and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT02864992 · Phase 2 · active, not recruiting

The study was open-label and had no randomized comparator arm, so the reported tumor responses cannot be distinguished from outcomes that might have occurred with other treatment or without tepotinib. Although response was assessed by an independent review committee and results were reported for 337 participants, the primary endpoint was descriptive in this single-arm design.

Next expected readout: December 2027 · NCT06083857 (registry estimate)

Reported efficacy

Objective response rate (ORR) by independent review committee (IRC): ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months (not_applicable)

Result source: NCT02864992

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSavolitinibTepotinib
PFS, median8.2 vs 4.5avs chemotherapyNCT050156084.9 vs 4.4vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
1 other result
  • 10.2 vs 4.3 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955
OS, median—Not posted · NCT0492394517.3 vs 19.5vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
ORR62.1%abNCT04923945
1 other result
45.2% vs 33.3%vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
2 other results
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955
Duration of response, median—Not posted · NCT04923945—Trial running · NCT06908993

PFS, median

Savolitinib
8.2 vs 4.5avs chemotherapyNCT05015608
Tepotinib
4.9 vs 4.4vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
1 other result
  • 10.2 vs 4.3 500 mg + 250 mg · n 31 · Phase 1/2 · secondary NCT01982955

OS, median

Savolitinib
—Not posted · NCT04923945
Tepotinib
17.3 vs 19.5vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955

ORR

Savolitinib
62.1%abNCT04923945
1 other result
Tepotinib
45.2% vs 33.3%vs Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg · n 31NCT01982955
2 other results
  • 33.3% 500 mg + 250 mg · n 12 · Phase 1/2 · secondary NCT01982955
  • 33.3% 300 mg + 250 mg · n 6 · Phase 1/2 · secondary NCT01982955

Duration of response, median

Savolitinib
—Not posted · NCT04923945
Tepotinib
—Trial running · NCT06908993
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Savolitinib: 1 of 5 rows · Tepotinib: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSavolitinib
Rows use multiple source trials
Tepotinib
ORR
responder rate · % of participants
No placebo or comparator arm
39.2%a,b,c,d,e
NCT04923945 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
62.1%
NCT04923945 · Phase 3 · sponsor-reported, not registry data
33.3% (n=12)500 mg + 250 mga,b,c,d,e
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
33.3% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Dropout rate—
0%500 mg + 250 mgf
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
0%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
0%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs—
—500 mg + 250 mgf
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
—500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs—
58.3%500 mg + 250 mgf
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
41.9%500 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
66.7%300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs—
500 mg + 250 mgf
diarrhoea 83.3%
dyspnoea exertional 41.7%
fatigue 41.7%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 2 more results
500 mg + 250 mg
diarrhoea 58.1%
oedema peripheral 38.7%
amylase increased 35.5%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
300 mg + 250 mg
amylase increased 66.7%
diarrhoea 66.7%
blood alkaline phosphatase increased 50%
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 1/2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tepotinib

Disease Control 58.3% (n=12)500 mg + 250 mg
responder rate · % of participants
No placebo or comparator arm
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more result
50% (n=6)300 mg + 250 mg
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival 17.25 vs 19.48 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
time to event · months
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
ORR 45.2% (n=31) vs 33.3% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg
responder rate · % of participants
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Disease Control 83.9% (n=31) vs 70.8% (n=24) Pemetrexed and Cisplatin/Carboplatin500 mg + 250 mg
responder rate · % of participants
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS -16.29 vs -2.78 Pemetrexed and Cisplatin/Carboplatin score500 mg + 250 mg
absolute change · score
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination
Time to Symptomatic Progression 5.75 vs 7.95 Pemetrexed and Cisplatin/Carboplatin months500 mg + 250 mg
time to event · months
NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Savolitinib's landscape · Tepotinib's landscape